Compass Therapeutics
CTX-009
Biliary Tract Cancer
Countdown
147days
Phase 3 readout · Dec 1, 2026
What's at stake
Phase 3 trial results for CTX-009 in Biliary Tract Cancer are due Dec 1, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT05506943: Phase 3 trial, sponsor Compass Therapeutics, drug CTX-009. Primary completion date 2026-12-01 (estimated).”